Zomedica Corp. (ZOM) |
| 0.0973 -0 (-0.21%) 03-04 09:50 |
| Open: | 0.092 |
| High: | 0.0973 |
| Low: | 0.092 |
| Volume: | 790,936 |
| Market Cap: | 95(M) |
| PE Ratio: | -1.62 |
| Exchange: | New York Stock Exchange Arca |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
| sell | buy | |||
| Resistance 2: | |
| Resistance 1: | |
| Pivot price: | |
| Support 1: | |
| Support 2: | |
| 52w High: | 0.1952 |
| 52w Low: | 0.0151 |
Zomedica Corp. is a veterinary healthcare enterprise dedicated to fulfilling the specific needs of clinical veterinarians through the creation of products for companion animals. The company is actively involved in the development and market introduction of its TRUFORMA platform, which delivers point-of-care diagnostic tools for various canine and feline illnesses. Additionally, Zomedica provides PulseVet, a system used to address a range of musculoskeletal conditions such as fractures, tendonitis, and torn ligaments in horses and smaller animals. Zomedica also maintains collaborative agreements, including one with Celsee, Inc. for the joint development and commercialization of liquid biopsy assays and consumables for detecting cancer in pets, and another with Seraph Biosciences, Inc. for the development and marketing of a novel pathogen detection system. Established in 2015 and based in Ann Arbor, Michigan, the company was formerly known as Zomedica Pharmaceuticals Corp. before adopting its current name in October 2020.
| EPS | |
| Book Value | |
| PEG Ratio | |
| Gross Profit |
| Profit Margin (%) | |
| Operating Margin (%) | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) |
Fri, 09 Oct 2026
Zomedica Announces "Fourth Friday at Four" Webinar on October 23, 2026: Zomedica's Clinical Program: How Evidence Drives Adoption - Lelezard
Wed, 09 Sep 2026
One marketing engine serves two kinds of animal-health products. Zomedica will explain how. - Stock Titan
Mon, 31 Aug 2026
Zomedica Corp. (ZOM) Key Financial Ratios – Valuation, Profitability & More - Value Research
Wed, 05 Aug 2026
Zomedica Announces Record Second Quarter Revenue of $9.5 Million, Up 37% Year-Over-Year, Net Loss Reduced 49%, with $44.1 Million in Liquidity - ACCESS Newswire
Fri, 07 Nov 2025
ZOMDF Stock Price and Chart — OTC:ZOMDF - TradingView
Thu, 06 Mar 2025
Zomedica (OTCPK:ZOMD.F) - Stock Analysis - Simply Wall Street
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |